Literature DB >> 32196851

Resveratrol for protection against statin toxicity in C2C12 and H9c2 cells.

Chama Attalah Nee Rezkallah1, Angkana Thongkum1, Chao Zhu1,2, Qin M Chen1,2.   

Abstract

Statins are among the most commonly prescribed drugs for the treatment of high blood cholesterol. Myotoxicity of statins in certain individuals is often a severe side effect leading to withdrawal. Using C2C12 and H9c2 cells, both exhibiting characteristics of skeletal muscle cells, we addressed whether resveratrol (RSV) can prevent statin toxicity. Statins decreased cell viability in a dose and time-dependent manner. Among the five statins tested, atorvastatin, simvastatin, lovastatin, pravastatin, and fluvastatin, simvastatin is the most toxic one. Simvastatin at 10 µM caused about 65% loss of metabolic activity as measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays in C2C12 cells or H9c2 cells. Inhibition of metabolic activity correlates with an increase in caspase activity. RSV was found to protect H9c2 cells from simvastatin-induced activation of caspase-3/7. However, such protection was not found in C2C12 cells. This cell type-dependent effect of RSV adds to the complexity in muscle cell toxicity of statins.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  cytotoxicity; lipid-lowering drug; metabolic inhibition; nutritional supplement

Mesh:

Substances:

Year:  2020        PMID: 32196851      PMCID: PMC8827215          DOI: 10.1002/jbt.22484

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  42 in total

1.  The role of nutraceutical supplements in the treatment of dyslipidemia.

Authors:  Mark Houston
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-01-17       Impact factor: 3.738

2.  Editorial commentary: The pleiotropic effect of statins on the atherosclerotic plaque and coronary heart disease.

Authors:  Antonis I Sakellarios; Dimitrios I Fotiadis
Journal:  Trends Cardiovasc Med       Date:  2019-02-10       Impact factor: 6.677

3.  Hydrogen peroxide dose dependent induction of cell death or hypertrophy in cardiomyocytes.

Authors:  Q M Chen; V C Tu; Y Wu; J J Bahl
Journal:  Arch Biochem Biophys       Date:  2000-01-01       Impact factor: 4.013

Review 4.  Antioxidant effects of resveratrol in the cardiovascular system.

Authors:  Ning Xia; Andreas Daiber; Ulrich Förstermann; Huige Li
Journal:  Br J Pharmacol       Date:  2016-05-06       Impact factor: 8.739

5.  One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease.

Authors:  João Tomé-Carneiro; Manuel Gonzálvez; Mar Larrosa; María J Yáñez-Gascón; Francisco J García-Almagro; José A Ruiz-Ros; María T García-Conesa; Francisco A Tomás-Barberán; Juan Carlos Espín
Journal:  Am J Cardiol       Date:  2012-04-19       Impact factor: 2.778

Review 6.  Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling and safety.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

Review 7.  Statins and cardioprotection--more than just lipid lowering?

Authors:  Andrew Ludman; Vinod Venugopal; Derek M Yellon; Derek J Hausenloy
Journal:  Pharmacol Ther       Date:  2009-01-23       Impact factor: 12.310

Review 8.  Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins.

Authors:  Dimitris Tousoulis; Costas Psarros; Michael Demosthenous; Rikhil Patel; Charalambos Antoniades; Christodoulos Stefanadis
Journal:  J Am Coll Cardiol       Date:  2014-03-05       Impact factor: 24.094

9.  Effects of resveratrol on the recovery of muscle mass following disuse in the plantaris muscle of aged rats.

Authors:  Brian T Bennett; Junaith S Mohamed; Stephen E Alway
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

10.  Resveratrol attenuates denervation-induced muscle atrophy due to the blockade of atrogin-1 and p62 accumulation.

Authors:  Yuka Asami; Miki Aizawa; Masakazu Kinoshita; Junji Ishikawa; Kunihiro Sakuma
Journal:  Int J Med Sci       Date:  2018-04-03       Impact factor: 3.738

View more
  2 in total

1.  Simvastatin Inhibits NLRP3 Inflammasome Activation and Ameliorates Lung Injury in Hyperoxia-Induced Bronchopulmonary Dysplasia via the KLF2-Mediated Mechanism.

Authors:  Xinye Wang; Ran Huo; Zhongjie Liang; Congcong Xu; Tingting Chen; Jingjing Lin; Luyao Li; Wei Lin; Bingting Pan; Xiaoqin Fu; Shangqin Chen
Journal:  Oxid Med Cell Longev       Date:  2022-04-25       Impact factor: 7.310

Review 2.  Pleiotropic use of Statins as non-lipid-lowering drugs.

Authors:  Qijia Zhang; Jianlong Dong; Ze Yu
Journal:  Int J Biol Sci       Date:  2020-08-13       Impact factor: 6.580

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.